Regadenoson .08 mg/mL

Regadenoson .08 mg/mL is a pharmaceutical solution used for specific medical imaging procedures. This intravenous injection is designed to enhance diagnostic accuracy in certain cardiovascular assessments.

Regadenoson .08 mg/mL is primarily used as a pharmacological stress agent in myocardial perfusion imaging (MPI). This injection helps to simulate the effects of physical exercise on the heart, aiding in the evaluation of coronary artery disease. Patients who are unable to undergo physical stress testing may benefit from this solution, as it provides an alternative method for assessing blood flow to the heart muscle.

Common effects of Regadenoson .08 mg/mL may include temporary increases in heart rate and blood pressure, as well as flushing or warmth. Some individuals might experience shortness of breath, dizziness, or headache. These effects are generally short-lived and subside quickly after administration.

Regadenoson .08 mg/mL should be handled with care, ensuring proper storage and administration by healthcare professionals. It is essential to follow all safety guidelines and protocols when using this injection. Patients with certain medical conditions or allergies should consult their healthcare provider before use.

Regadenoson .08 mg/mL may interact with other medications, particularly those affecting heart rate or blood pressure. It is important to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain substances may also influence the effects of this injection.